Prevalence, health care utilization, and costs of fibromyalgia, irritable bowel, and chronic fatigue syndromes in the military health system, 2006–2010

Military Medicine

Volumn 179, Issue 9, 2014, Pages 1021-1029

  Jeffery, Diana D ^a   Bulathsinhala, Lakmini ^b   Kroc, Michelle ^c   Dorris, Joseph ^c  

^a TRICARE Management Activity   (United States)

^b U S ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE   (United States)

^c ALTARUM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; COMPARATIVE STUDY; COST OF ILLNESS; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMAN; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; MILITARY MEDICINE; PATIENT ATTITUDE; PREVALENCE; UNITED STATES;

ADOLESCENT; ADULT; COST OF ILLNESS; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; MILITARY MEDICINE; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; UNITED STATES;

EID: 84928502174     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.7205/MILMED-D-13-00419     Document Type: Article

References (53)

1. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L: Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105(4): 848-58.
2. Kroenke K: Comparing fibromyalgia across different clinical settings: is it apples and oranges, or oranges and tangerines? Eur J Pain 2011; 15(9): 887-8, 999-1000.
3. Toda K: The term of functional somatic syndrome should be changed to the term of central sensitivity syndrome. Pain Practice 2012; 12(1): 83.
4. Christley Y, Duffy T, Martin CR: A review of the definitional criteria for chronic fatigue syndrome. J Eval Clin Pract 2012; 18(1): 25-31.
5. Agüera L, Failde I, Cervilla JA, Díaz-Fernández P, Mico JA: Medically unexplained pain complaints are associated with underlying unrecognized mood disorders in primary care. BMC Fam Pract 2010; 11: 17.
6. Klaus K, Rief W, Brähler E, Martin A, Glaesmer H, Mewes R: The distinction between "medically unexplained" and "medically explained" in the context of somatoform disorders. Int J Behav Med 2013; 20(2): 161-71.
7. Fietta P, Fietta P, Manganelli P: Fibromyalgia and psychiatric disorders. Acta Biomedic 2007; 78(2): 88-95.
8. Dansie EJ, Furberg H, Afari N, et al: Conditions comorbid with chronic fatigue in a population-based sample. Psychosomatics 2012; 53(1): 44-50.
9. Cella M, White PD, Sharpe M, Chalder T: Cognitions, behaviours and co-morbid psychiatric diagnoses in patients with chronic fatigue syndrome. Psychol Med 2013; 43(2): 375-80.
10. Lackner JM, Ma CX, Keefer LA, et al: Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clinical Gastroenterol Hepatol 2013; 11(9): 1147-57.
11. Maguen S, Madden E, Cohen B, Bertenthal D, Seal K: Association of mental health problems with gastrointestinal disorders in Iraq and Afghanistan veterans. Depress Anxiety 2014; 31(2): 160-5.
12. Poeschla B, Strachan E, Dansie E, Buchwald DS, Afari N: Chronic fatigue and personality: a twin study of causal pathways and shared liabilities. Ann Behav Med 2013; 45(3): 289-98.
13. Christley Y, Duffy T, Everall IP, Martin CR: The neuropsychiatric and neuropsychological features of chronic fatigue syndrome: revisiting the enigma. Curr Psychiatry Rep 2013; 15: 353.
14. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Available at http://www.cdc.gov/arthritis/basics/fibromyalgia.htm; accessed September 15, 2013.
15. Painter JT, Crofford LJ, Talbert J: Geographic variation of chronic opioid use in fibromyalgia. Clin Ther 2013; 35(3): 303-11.
16. DiBonaventura M, Sun SX, Bolge SC, Wagner JS, Mody R: Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011; 27(11): 2213-22.
17. Lovell RM, Ford AC: Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107(7): 991-1000.
18. Jason LA, Porter N, Hunnell J, Rademaker A, Richman JA: CFS prevalence and risk factors over time. J Health Psychol 2011; 16(3): 445-56.
19. Li B, Mahan CM, Kang HK, Eisen SA, Engel CC: Longitudinal health study of US 1991 Gulf War veterans: changes in health status at 10-year follow-up. Am J Epidemiol 2011; 174(7): 761-8.
20. Eisen SA, Kang HK, Murphy FM, et al: Gulf War veterans' health: medical evaluation of a U.S. cohort. Ann Intern Med 2005; 142(11): 881-90.
21. Edson JN, Ingegno AP, D'Albora JB: Irritable colon: experience with 122 cases in an Army general hospital. Med Times 1946; 74: 6-8.
22. Nyrop KA, Palsson OS, Levy RL, et al: Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007; 6(2): 237-48.
23. Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G: Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care 2010; 16(5 Suppl): S126-37.
24. Haviland MG, Banta JE, Przekop P: Hospitalisation charges for fibromyalgia in the United States, 1999-2007. Clin Exp Rheumatol 2012; 30(6 Suppl 74): 129-35.
25. Palacio A, Uribe CL, Li H, et al: Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care 2010; 16(5 Suppl): S118-25.
26. Ladabaum U, Boyd E, Zhao WK, et al: Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 2012; 10(1): 37-45.
27. Lachaine J, Beauchemin C, Landry PA: Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010; 26(4): 284-90.
28. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G: The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm 2012; 18(6): 415-26.
29. Sanchez RJ, Uribe C, Li H, et al: Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr Med Res Opin 2011; 27(3): 663-71.
30. Longstreth GF, Wilson A, Knight K, et al: Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98(3): 600-7.
31. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S: The economic impact of ME/CFS: individual and societal costs. Dyn Med 2008; 7: 6.
32. Reed C, Birnbaum HG, Ivanova JI, et al: Real-world role of tricyclic antidepressants in the treatment of fibromyalgia. Pain Pract 2012; 12(7): 533-40.
33. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D: Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ 2012; 15(1): 19-31.
34. Barker KK: Listening to Lyrica: contested illnesses and pharmaceutical determinism. Soc Sci Med 2011; 73(6): 833-42.
35. Wolfe F, Clauw DJ, Fitzcharles MA, et al: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011; 38(6): 1113-22.
36. Treadwell BJ: Fibromyalgia. N Z Med J 1981; 94(690): 157-8.
37. U.S. Justice Department. 2009. Settlement Agreement. Available at http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20Settlement%20Agreement.pdf; accessed September 15, 2013.
38. Kornfield R, Donohue J, Berndt ER, Alexander GC: Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One 2013; 8(3): e55504.
39. Pfizer. 2009. U.S. Medical, Scientific and Patient Organization Grants & Charitable Contributions. Available at http://www.pfizer.com/files/responsibility/grants_contributions/pfizer_us_grants_cc_q4_2008.pdf; accessed September 15, 2013.
40. Mease P, Berney S, Arnold L, et al: Fibromyalgia diagnostic and treatment challenges: Results from a recent summit of fibromyalgia experts. Medscape. Available at http://www.medscape.org/viewarticle/701757; accessed March 27, 2014.
41. Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, Häuser W: Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013; 2013: 485272.
42. Üçeyler N, Sommer C, Walitt B, Häuser W: Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2013; 10: CD010782.
43. Wiffen PJ, Derry S, Moore RA, et al: Antiepileptic drugs for neuropathic pain and fibromyalgia-an overview of Cochrane reviews. Cochrane Database Syst Rev 2013; 11: CD010567.
44. Lunn MP, Hughes RA, Wiffen PJ: Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 1: CD007115.
45. Busse JW, Ebrahim S, Connell G, et al: Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol. Syst Rev 2013; 2: 18.
46. Health Care Cost Institute. Health Care Cost and Utilization Report: 2010. Available at http://www.healthcostinstitute.org/files/HCCI_HCCUR2010.pdf; accessed September 15, 2013.
47. Department of Defense-Health Affairs. Evaluation of the TRICARE Program: Access, Cost, Quality Fiscal Year 2013 Report to Congress. Available at http://tricare.mil/tma/dhcape/program/downloads/TRICARE2013%2002_28_13%20v2.pdf; accessed February 3, 2014.
48. Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group. Available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/proj2010.pdf; accessed September 15, 2013.
49. Hoffman JM, Shah ND, Vermeulen LC, et al: Projecting future drug expenditures-2008. Am J Health Syst Pharm 2008 Feb 1; 65(3): 234-53.
50. Hoffman JM, Doloresco F, Vermeulen LC, et al: Projecting future drug expenditures-2010. Am J Health Syst Pharm 2010 Jun 1; 67(11): 919-28.
51. Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y: Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat 2013; 2013: 898493.
52. Department of Defense-Health Affairs. Uniform Formulary Beneficiary Advisory Panel Minutes, 12 January 2012. Available at http://www.tricare.mil/tma/pharmacy/BAP/documents/Combined%20File%20-20BAP.PDF; accessed February 3, 2014.
53. Suehs BT, Lauder A, Udall M, Cappelleri JC, Joshi AV, Patel NC: Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. Pain Pract 2014; 14(5): 419-26.